


# LSP Life Sciences Fund

**LSP**  
Life Sciences Partners

Monthly Report December 2013

NAV per Share € 133.95



NAV of Fund	62,592,519
Number of Shares	467,271
Valuation Date	31/12/2013
Inception date:	27/04/2011
Currency:	Euro
Domicile:	The Netherlands
Legal Structure:	Dutch NV with variable capital
Listing:	Euronext Amsterdam
Euronext code:	LSP
ISIN Code:	NL0009756394
Bloomberg:	LSP NA

## Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below € 1 billion at the time of investment.

## Manager's comments




In the month of December, the Fund continued its rally to close the year at a share price of almost € 134, the highest end-of-month price achieved to date. AcclRx saw its share price increase further following the announcement of a major strategic alliance with Grunenthal for EU commercialization of its lead pain product, Zalviso. Furthermore, the company secured an additional \$ 40 million in non-dilutive financing to further strengthen its balance sheet. Synergy Pharmaceuticals also had a strong performance this month in anticipation of important Phase IIb clinical data from its lead compound plecanatide, expected in Q1 2014. Optos, a UK based medical device company with a unique instrument to view the back of the eye, saw its share price jump following the announcement of improved financials. GW Pharma continued its significant rally, which started since the Fund initiated its position in the company last September.

Overall, 2013 has proven to be an excellent year for the LSP Life Sciences Fund, which generated a return for the year of 29%. Going into 2014, we anticipate strong news flow from our portfolio companies and see many exciting new opportunities for the year ahead.

## Top-5 performers

1. Synergy Pharma. + 22.9%
2. Optos + 17.3%
3. AcclRx + 15.6%
4. GW Pharma. + 13.8%
5. Amarin + 8.2%

## Portfolio breakdown



## Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment- and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via [www.lsplifesciencesfund.com](http://www.lsplifesciencesfund.com).

# LSP Life Sciences Fund



## Top-10 portfolio positions

<b>Company</b>	<b>Stage</b>	<b>Subsector</b>	<b>Marketcap</b>	<b>%</b>
AcelRX	Late	Medical Device	Small	13.6%
BTG	Market	Specialty Pharma	Mid	9.2%
Lombard Medical	Late	Medical Device	Micro	8.9%
Optos	Market	Medical Device	Small	8.7%
GW Pharmaceuticals	Market	Therapeutics	Small	7.3%
MorphoSys	Early	Therapeutics	Mid	6.7%
Synergy Pharmaceuticals	Late	Therapeutics	Small	5.9%
Ablynx	Early	Therapeutics	Small	5.6%
Neurocrine Biosciences	Late	Therapeutics	Small	5.3%
Basilea Pharmaceutica	Market	Therapeutics	Small	4.8%